BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (BRTX)
NASDAQ:AMEX Investor Relations:
biorestorative.com/content/investor-relations
Company Research
Source: GlobeNewswire
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical designEnrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced completion of patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of BRTX-100 for the treatment of chronic lumbar disc disease (“cLDD”). BRTX-100 is BioRestorative’s lead clinical candidate — an autologous, hypoxically cultured mesenchymal stem cell therapy engineered for delivery into low-oxygen,
Show less
Read more
Impact Snapshot
Event Time:
BRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRTX alerts
High impacting BioRestorative Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
BRTX
News
- BioRestorative prices $5M stock offering [Seeking Alpha]Seeking Alpha
- BioRestorative Announces Pricing of $5.0 Million Public OfferingGlobeNewswire
- BioRestorative Announces Positive Outcome from Type B Meeting with FDAGlobeNewswire
- ?????????????????????????????2035????18?6170??????49?5700???????????????(CAGR)10.29%???????????? [CNET News]CNET News
- Biorestorative Therapies (NASDAQ:BRTX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
BRTX
Sec Filings
- 2/12/26 - Form EFFECT
- 2/10/26 - Form S-1/A
- 2/9/26 - Form S-1
- BRTX's page on the SEC website